{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:16:18Z","timestamp":1792718178331,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An acquired somatic mutation, Jak2V617F, was recently discovered in most patients with polycythemia vera (PV), chronic idiopathic myelofibrosis (CIMF), and essential thrombocythemia (ET). To investigate the role of this mutation in vivo, we transplanted bone marrow (BM) transduced with a retrovirus expressing either Jak2 wild-type (wt) or Jak2V617F into lethally irradiated syngeneic recipient mice. Expression of Jak2V617F, but not Jak2wt, resulted in clinicopathologic features that closely resembled PV in humans. These included striking elevation in hemoglobin level\/hematocrit, leukocytosis, megakaryocyte hyperplasia, extramedullary hematopoiesis resulting in splenomegaly, and reticulin fibrosis in the bone marrow. Histopathologic and flow cytometric analyses showed an increase in maturing myeloid lineage progenitors, although megakaryocytes showed decreased polyploidization and staining for acetylcholinesterase. In vitro analysis of primary cells showed constitutive activation of Stat5 and cytokine-independent growth of erythroid colony-forming unit (CFU-E) and erythropoietin hypersensitivity, and Southern blot analysis for retroviral integration indicated that the disease was oligoclonal. Furthermore, we observed strain-specific differences in phenotype, with Balb\/c mice demonstrating markedly elevated leukocyte counts, splenomegaly, and reticulin fibrosis compared with C57Bl\/6 mice. We conclude that Jak2V617F expression in bone marrow progenitors results in a PV-like syndrome with myelofibrosis and that there are strain-specific modifiers that may in part explain phenotypic pleiotropy of Jak2V617F-associated myeloproliferative disease in humans.<\/jats:p>","DOI":"10.1182\/blood-2005-12-4824","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T02:53:44Z","timestamp":1139972024000},"page":"4274-4281","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":425,"title":["Expression of Jak2V617F causes a polycythemia vera\u2013like disease with associated myelofibrosis in a murine bone marrow transplant model"],"prefix":"10.1182","volume":"107","author":[{"given":"Gerlinde","family":"Wernig","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mercher","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Okabe","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gary","family":"Gilliland","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, the Howard Hughes Medical Institute, and the Department of Pathology, Brigham and Women's Hospital, Boston; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111715120891300_REF1","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-1148.","DOI":"10.1038\/nature03546"},{"key":"2019111715120891300_REF2","doi-asserted-by":"crossref","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7: 387-397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2019111715120891300_REF4","doi-asserted-by":"crossref","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352: 1779-1790.","DOI":"10.1056\/NEJMoa051113"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106: 3370-3373.","DOI":"10.1182\/blood-2005-05-1800"},{"key":"2019111715120891300_REF6","doi-asserted-by":"crossref","unstructured":"Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106: 2162-2168.","DOI":"10.1182\/blood-2005-03-1320"},{"key":"2019111715120891300_REF7","doi-asserted-by":"crossref","unstructured":"Fialkow PJ, Reddy AL, Bryant JI. Clonal origin and trisomy of chromosome 15 in murine B-cell malignancies. Int J Cancer. 1980;26: 603-608.","DOI":"10.1002\/ijc.2910260512"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol. 2005; 84: 250-257.","DOI":"10.1007\/s00277-004-0977-1"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6: 372-375.","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Prchal JT, Guan YL, Prchal JF, Barany F. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis. Blood. 1993; 81: 269-271.","DOI":"10.1182\/blood.V81.1.269.269"},{"key":"2019111715120891300_","doi-asserted-by":"crossref","unstructured":"Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295: 913-916.","DOI":"10.1056\/NEJM197610212951702"},{"key":"2019111715120891300_REF12","doi-asserted-by":"crossref","unstructured":"Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105: 4187-4190.","DOI":"10.1182\/blood-2005-03-1287"},{"key":"2019111715120891300_REF13","doi-asserted-by":"crossref","unstructured":"Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [letter]. N Engl J Med. 1974; 290: 1382.","DOI":"10.1056\/NEJM197406132902419"},{"key":"2019111715120891300_REF14","doi-asserted-by":"crossref","unstructured":"Reid CD. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Rev. 1987;1: 133-140.","DOI":"10.1016\/0268-960X(87)90008-7"},{"key":"2019111715120891300_REF15","doi-asserted-by":"crossref","unstructured":"Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101: 3294-3301.","DOI":"10.1182\/blood-2002-07-2287"},{"key":"2019111715120891300_REF16","doi-asserted-by":"crossref","unstructured":"Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93: 385-395.","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"2019111715120891300_REF17","doi-asserted-by":"crossref","unstructured":"Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93: 397-409.","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"2019111715120891300_REF18","doi-asserted-by":"crossref","unstructured":"Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL\/JAK2 fusion genes. EMBO J. 1998;17: 5321-5333.","DOI":"10.1093\/emboj\/17.18.5321"},{"key":"2019111715120891300_REF19","doi-asserted-by":"crossref","unstructured":"Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99: 310-318.","DOI":"10.1182\/blood.V99.1.310"},{"key":"2019111715120891300_REF20","doi-asserted-by":"crossref","unstructured":"Jackson CW, Brown LK, Somerville BC, Lyles SA, Look AT. Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. Blood. 1984;63: 768-778.","DOI":"10.1182\/blood.V63.4.768.768"},{"key":"2019111715120891300_REF21","doi-asserted-by":"crossref","unstructured":"Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106: 494-504.","DOI":"10.1182\/blood-2004-08-3280"},{"key":"2019111715120891300_REF22","doi-asserted-by":"crossref","unstructured":"Gonsky R, Deem RL, Bream J, Young HA, Targan SR. Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression. J Immunol. 2004; 173: 6241-6247.","DOI":"10.4049\/jimmunol.173.10.6241"},{"key":"2019111715120891300_REF23","unstructured":"Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89: 1194-1198."},{"key":"2019111715120891300_REF24","doi-asserted-by":"crossref","unstructured":"Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood. 2005;106: 2862-2864.","DOI":"10.1182\/blood-2005-04-1515"},{"key":"2019111715120891300_REF25","doi-asserted-by":"crossref","unstructured":"Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102: 18962-18967.","DOI":"10.1073\/pnas.0509714102"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4274\/1279579\/zh801106004274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/11\/4274\/1279579\/zh801106004274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T18:16:22Z","timestamp":1586715382000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/11\/4274\/22015\/Expression-of-Jak2V617F-causes-a-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-12-4824","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}